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RNA splicingMutant ribonucleic acid (RNA) molecules can be toxic to the cell, causing human disease through trans-acting
dominant mechanisms. RNA toxicity was ﬁrst described in myotonic dystrophy type 1, a multisystemic dis-
order caused by the abnormal expansion of a non-coding trinucleotide repeat sequence. The development
of multiple and complementary animal models of disease has greatly contributed to clarifying the complex
disease pathways mediated by toxic RNA molecules. RNA toxicity is not limited to myotonic dystrophy and
spreads to an increasing number of human conditions, which share some unifying pathogenic events medi-
ated by toxic RNA accumulation and disruption of RNA-binding proteins. The remarkable progress in the dis-
section of disease pathobiology resulted in the rational design of molecular therapies, which have been
successfully tested in animal models. Toxic RNA diseases, and in particular myotonic dystrophy, clearly illus-
trate the critical contribution of animal models of disease in translational research: from gene mutation to
disease mechanisms, and ultimately to therapy development. This article is part of a Special Issue entitled:
Animal Models of Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The abnormal expansion of trinucleotide repeat sequences was ﬁrst
identiﬁed as the cause of human diseases more than twenty years ago,
in fragile-X syndrome [1–4] and spinobulbar muscular atrophy (SBMA)
or Kennedy disease [5]. Over the two decades that followed, a fast grow-
ing number of human inherited diseases have been associated with the
expansion of trinucleotide repeats at speciﬁc chromosomal loci, such as
myotonic dystrophy type 1 (DM1), Huntington disease (HD), Friedreich
ataxia (FRDA), dentatorubral-pallidoluysian atrophy (DRPLA) and many
spinocerebellar ataxias (SCAs) [6–8]. Typically, the number of triplet re-
peats in non-affected individuals is lower than 30, but it is higher than
40–50 in patients, and it may exceed 1000 repeats in the most severe
clinical forms of certain diseases. Longer repeat tracts are genetically un-
stable andundergo further expansion during intergenerational transmis-
sion. Since the repeat size shows a broad direct correlation with disease
severity, and inverse correlation with age of onset, expansion-biased
intergenerational instability leads to anticipation (a hallmark of most
dominant trinucleotide repeat disorders), whereby the disease symp-
tomsworsen anddevelop earlier in successive generations. Trinucleotide
repeat size mutations can also occur in somatic tissues, resulting inl Models of Disease.
-Enfants Malades, 75015 Paris,
4.
-Pereira).
l rights reserved.the accumulation of tissue-speciﬁc, age-dependent, expansion-biased
somaticmosaicism,whichmost likely contributes to the phenotypic var-
iability and progression of disease over time [7,9,10].
Despite the similar genetic defect shared by these conditions, the
downstream pathophysiology can be mediated by multiple pathways.
This diversity in molecular pathogenesis is partially due to the different
locations of the expanded repeat within a variety of otherwise unrelated
genes. The expanded repeat tract can be located in protein-coding se-
quences, and therefore affect the ﬁnal gene product of the mutant gene.
This is the case in CAG expansion disorders (e.g.: HD, SBMA, DRPLA,
SCA1, SCA2, SAC3/MJD, SCA7 and SCA17), whosemolecular pathogenesis
appears to be primarily mediated by a deleterious gain of function of the
polyglutamine tract encoded by the expanded trinucleotide sequence
[11]. Although not changing the ﬁnal protein sequence, non-coding trip-
let repeats can also be pathogenic. Untranslateddisease-associated repeat
expansions can map in the 5′ or 3′ untranslated regions (UTRs), pro-
moters or introns of the affected gene. In FRDA, the intronic GAA expan-
sion interferes with transcription and reduces the mRNA and protein
levels of the FXN/frataxin gene [12]. The expanded CGG repeat in fragile
X syndrome, on the other hand, maps within the promoter of the FMR1
gene, causing DNA methylation and promoter inactivation [13]. In both
cases, disease pathogenesis is explained by loss of function of the expand-
ed gene. Nonetheless, gain of function mechanisms, like those operating
at the RNA level in DM1, can also be triggered by untranslated trinucleo-
tide repeat expansions.
Soon after the identiﬁcation of disease-associated trinucleotide re-
peat expansions, great effort was put into the generation of transgenic
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peat size mutation [14], but also to gain insight into the intricate se-
quence of molecular events that connect the expansion of simple DNA
repeats to the development of complex disease symptoms. The contri-
bution of animal models to the dissection of disease mechanisms is
clearly illustrated in myotonic dystrophy, for which multiple mouse
lines have been generated over the years. Following the identiﬁcation
of the CTG trinucleotide repeat as the genetic cause of DM1 in 1992
[15–17], the ﬁrst transgenic mice recreating DM1-associated repeat
instability were reported in 1997 [18,19]. Less than ten years following
the identiﬁcation of the DM1 mutation, transgenic mouse models
provided solid evidence of a novel disease mechanism mediated by
toxic RNA transcripts [20,21]. Transcription of non-coding DNA repeats
produces expanded RNA transcripts that are deleterious to the cell,
disturbing multiple downstream cellular processes and causing com-
plex multisystemic disorders [22,23]. The generation of multiple and
complementary disease animal models through the years (mainly
mice, but also transgenic ﬂies, ﬁsh and worms) resulted in the ﬁne-
tuning of the mechanisms of RNA toxicity, for which DM1 became the
paradigm. Today we know that disease-causing RNA likely mediates
the molecular pathogenesis of other conditions, most of them caused
by the expansion of non-coding repeat sequences, such as DM type 2
(DM2) [24], fragile X tremor ataxia syndrome (FXTAS) [25], SCA type
8 (SCA 8) [26], SCA 10 [27], SCA 12 [28], SCA 31 [29], SCA 36 [30],
Huntington disease-like 2 (HDL2) [31] and amyotrophic lateral sclerosis
(ALS) [32]. Toxic RNAs have also been implicated in polyglutamine ex-
pansion disorders primarilymediated by proteotoxicity [33], suggesting
that the contribution of RNA toxicity to diseasemight havewider impli-
cations than previously thought, and participate in multiple human
conditions.
Recently, therapeutic strategies targeting speciﬁc steps of the
pathobiological cascade were tested in DM1 animal models and
yielded promising results [34–38]. The research path from the identi-
ﬁcation of disease mutation to the pre-clinical development of prom-
ising therapies took less than 20 years. During this period DM1
became not only a paradigm of RNA toxicity, but also a clear example
of using animal models for the step-by-step dissection of complex
mechanisms of human disease and rational therapy design. DM1 re-
search has moved forward, from the clinic to the laboratory with
the development of relevant disease models for academic research.
The ﬁeld is now returning to the clinic and human patients, offering
the hope of efﬁcient therapies. In this review, we will cover the con-
tribution of animal models to this path. We will review the current
understanding of RNA toxicity, focusing primarily on DM.Wewill dis-
cuss the current model of toxic RNA accumulation and missplicing,
integrate recent ﬁndings into this model, review the latest progress
in therapy development and discuss data that do not ﬁt into the cur-
rent working hypothesis.
2. A new disease intermediate: Non-coding expanded RNA repeats
DM is a highly multisystemic disorder, mainly characterised by
myotonia, muscle weakness and wasting, cardiac conduction defects,
neuropsychological manifestations, premature cataracts and insulin
resistance [39]. Intergenerational instability and anticipation contrib-
ute to the phenotypic variability of the disease, resulting in different
clinical forms, from a mild late onset, to the most severe congenital
cases. Two clinically similar, but genetically distinct forms of the dis-
ease have been described: DM type 1 (DM1) and DM type 2 (DM2).
DM1 is caused by the expansion of a non-coding CTG trinucleotide re-
peat in the 3′UTR of the dystrophia myotonica protein kinase (DMPK)
gene [15–17], which overlaps with the promoter region of the down-
stream sine oculis related homeobox 5 (SIX5) gene [40]. DM2 is caused
by a CCTG tetranucleotide repeat expansion in the ﬁrst intron of the
unrelated CCHC-type zinc ﬁnger nucleic acid binding protein (CNBP)
gene, previously known as zinc ﬁnger 9 (ZNF9) [24].2.1. Early evidence of RNA toxicity in DM1 and DM2
The clinical and molecular similarities between DM1 and DM2 have
helped uncover the role of expanded RNA repeats in DM pathogenesis.
In both conditions, expandedRNA transcripts are retained in the nucleus,
forming RNA aggregates (or foci) [24,41,42]. The accumulation of ribo-
nucleic inclusions in DM1 and DM2 suggested abnormal gain of function
mediated by expanded CUGRNA repeats in DM1, and CCUGRNA repeats
in DM2. Today we know that RNA foci are dynamic protein-containing
structures, which represent an important hallmark of toxic RNA disor-
ders. The abnormal interaction between expanded RNA molecules and
RNA-binding proteins contributes to cell dysfunction and disease pheno-
types. In the search for proteins capable of mediating the deleterious ef-
fect of expanded RNAs in DM1, two families of splicing regulators were
identiﬁed: MBNL (muscleblind-like) and CELF (CUGBP, Elav-like family)
proteins. MBNL proteins bind double-stranded RNA hairpins [43]. All
three mammalian protein isoforms (MBNL1, MBNL2 and MBNL3) are
recruited to the nuclear RNA foci in DM1 and DM2 cells, presumably
resulting in functional depletion [44]. CELF1 does not localise with RNA
foci [45]. Instead this protein was identiﬁed through its capacity to
bind CUG RNA repeats in vitro [46], and found to be upregulated in
DM1 samples [47–50]. The situation is less clear in DM2, with conﬂicting
reports of normal [51,52] and increasing CELF1 protein levels [53] in pa-
tient tissues and cells.
The abnormal localisation and/or protein levels of important splic-
ing regulators, and the characterisation of splicing abnormalities in
DM1 and DM2 [47–50,54] provided the ﬁrst evidence of a unifying
pathogenicmechanismmediated, at least partly, by aberrant RNA splic-
ing (Fig. 1). Transgenic animalmodels generated deﬁnitive proof of RNA
toxicity in DM, and demonstrated the central role of MBNL and CELF
proteins in disease pathogenesis (Fig. 2).
2.2. Transgenic mouse models of RNA toxicity
The ultimate evidence of the trans-dominant role of toxic CUG RNA
repeats came from transgenic mice engineered to express non-coding
CUG repeats in an unrelated gene [21] (Table 1, Fig. 2). The HSALR
mice express human skeletal actin (HSA) transcripts containing ~250
CTG trinucleotide repeats within its 3′UTR. The expression of expanded
HSA transcripts in the skeletal muscle resulted in DM1-like myotonic
discharges at four weeks of age, and mild signs of myopathy at later
stages [21]. The occurrence of myotonia in the absence of histological
abnormalities suggests that HSALR mice recreate a genuine myotonic
disorder resulting from the accumulation of toxic RNA transcripts, rath-
er than a non-speciﬁc hyperexcitability secondary to muscle necrosis.
The positive correlation found between the expression levels of ex-
panded HSALR transcripts in different founder lines, and the degree of
missplicing, myotonia and myopathy [21,55], further supported a
dose-dependent effect of the levels of toxic CUG repeats on muscle
physiology. The analysis of the cellular distribution of MBNL1 in re-
sponse to the accumulation of CUG-containing transcripts revealed sig-
niﬁcant recruitment of this splicing regulator into ribonuclear foci,
illustrated by a decrease to 20% of mean immunoﬂuorescence intensity
of MBNL1 in the nucleoplasm ofHSALR skeletal muscle (exclusive of nu-
clear foci), when compared to wild-type controls [21,51]. As a result of
MBNL1 sequestration into nuclear foci, HSALR mice showed deregula-
tion of the alternative splicing of a set of transcripts in skeletal muscle
[51,55]. The initial ﬁndings of normal steady-state CELF1 protein levels
inHSALR quadriceps [51] suggested that the sequestration ofMBNL pro-
teins was sufﬁcient to trigger at least some key DM features in adult
skeletalmuscle. However, reports of CELF1 upregulation inHSALR soleus
[56] have challenged this hypothesis and supported the implication of
CELF1 in muscle pathology.
This work has clearly demonstrated the deleterious consequences
of CUG RNA repeats to skeletal muscle by inducing key features of the
disease, such a myotonia, independently of the surrounding genomic
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Fig. 1. Molecular pathogenesis of DM1. Expanded DMPK transcripts accumulate in the cell nucleus and are not appropriately exported to the cytoplasm. Toxic RNA accumulation
affects the localisation and steady-state levels of multiple RNA-binding proteins, disturbing their function and having an impact on downstream targets. MBNL sequestration
into RNA foci and functional inactivation dysregulates missplicing, gene expression and miRNA metabolism. Hyperphosphorylation-mediated CELF1 upregulation perturbs alterna-
tive splicing and protein translation. Increased hnRNP H levels may contribute to abnormal splicing. Transcription activation of NKX2-5 causes expression abnormalities of target
genes. Similarly, sequestration of SP1 and RARγ transcription factors by expanded transcripts away from active chromatin likely disturbs gene expression. The cytoplasmic
mislocalisation and subsequent inactivation of the transcriptional regulator SPEN/SHARP likely contributes to abnormal gene expression. Finally, the partial recruitment and
co-localisation of DDX5/p68 with RNA foci may have a contributing role in the dysregulation of the splicing of a subset of RNA transcripts.
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wasting in these mice suggests a role of the non-repetitive DMPK 3′
UTR sequences ﬂanking the CUG repeat. In addition, given the tissue-
speciﬁcity of transgene expression in HSALR mice, the plausible toxicity
of RNA transcripts in other tissues remained to be demonstrated.
The multisystemic impact of CUG expansions was illustrated in
DM300 transgenic mice expressing full-length expanded DMPK tran-
scripts (bearing 300–600CTG repeats) inmultiple tissues, under the con-
trol of the human promoter (Table 1). Transgene expression in these
mice resulted in the accumulation of ribonuclear foci in various tissues
[20,57] and in the development of relevant muscle phenotypes (myoto-
nia, myopathy, progressive muscle weakness), signs of tauopathy in the
CNS similar to the human condition [20], as well as abnormal glucose
metabolism [57], growth retardation and marked mortality [20]. The
physiological, histological and molecular phenotypes were observed in
homozygous mice and were more pronounced in mice carrying larger
CTG expansions. These observations show that the expression levels of
toxic RNA molecules and the length of the CTG repeat are determinant
factors for the development of disease phenotypes. DMSXL mice (carry-
ing ~1000–1800 CTG repeats in the same integration site) exhibit higher
mortality, more severe reduction in body weight and splicing dysreg-
ulation [58,59], aswell as deﬁcits inmotor performance [59], behavioural
abnormalities and synaptic dysfunction [60]. No abnormalities were
found in the control DM20 line, expressing short DMPK transcripts
with 20 CTG repeats.
Further evidence of the pathogenic role of expanded RNAs was
provided by an inducible Cre-lox mousemodel, engineered to express
960 interrupted and untranslated CTG repeats within DMPK exon 15
(Table 1). Transgene expression in the heart of EpA960 mice resulted
in severe cardiomyopathy, including cardiac arrhythmia leading to
death within two weeks [61]. Transgene expression in skeletal muscle
has also resulted in characteristic DM phenotypes, such as myotonic
discharges, progressive muscle wasting, deﬁcits in muscle perfor-
mance and histopathological abnormalities [62]. The physiological
phenotypes in cardiac and skeletal muscles of EpA960 mice were ac-
companied by nuclear RNA foci accumulation, MBNL1 sequestration,
CELF1 and CELF2 upregulation and splicing defects [61,62].Taken together, these mouse models have unequivocally demon-
strated the central role of toxic RNA repeats in DM pathogenesis,
and suggested a unifying disease mechanism mediated by the essen-
tial nuclear localisation and accumulation of expanded transcripts for
pathogenesis (Fig. 2). Even though cytoplasmic RNA foci have been
reported in DM1 ﬁbroblasts and myoblasts [63], as well as in CUG-
or CCUG-transfected cells [64,65], transgenic mice that accumulate
CUG-containing ribonuclear foci predominantly in the cytoplasm do
not recreate characteristic DM phenotypes [63]. The physiological im-
pact of cytoplasmic RNA foci is not fully understood.
Depending on the temporal and spatial control of transgene expres-
sion, each of thesemouse lines exhibits advantages and limitations [66].
In reality, they complement each other towards a greater understand-
ing of disease biology and the development of rational therapies. De-
spite the prevalent contribution of mouse lines in deciphering RNA
toxicity, toxic RNAmechanisms have also been reproduced and investi-
gated in other model organisms.2.3. Other animal models of RNA toxicity
The processes underlying the formation of CUG-containing foci are
conserved in Drosophila. Flies expressing 162 CTG repeats in the 3′
UTR of a GFP reporter gene showed nuclear foci that co-localise with
muscleblind [67]. Despite ubiquitous transgene expression, only a subset
of adult muscle cells showed RNA foci, indicating that cell type-speciﬁc
factors must mediate the retention of CUG-containing transcripts in the
nucleus. Surprisingly, no deleterious phenotype was detected in these
ﬂies, suggesting that neither (CUG)162 repeat expansions in this genomic
context, nor the accumulation of RNA foci is toxic to Drosophila per se
[67]. In contrast, the expression of non-coding CTG sequences longer
than 250 repeats causedmuscle, eye and brain phenotypes in association
with RNA foci, muscleblind sequestration [68] and missplicing [69]. The
pathological phenotypes of these lines might be explained by a length-
dependent effect, or by the contributing role of the genomic context sur-
rounding the CUG repeat. In fact, independent Drosophila lines express-
ing non-coding CTG expansions in different integration sites displayed
CUG-expressing Caenorhabditis elegans
 * Wang et al. Cell. Mol. Life Sci. 68 (2011) 1255-1267
 * Chen et al. Biochem. Biophys. Res. Commun. 352 (2007) 774-779
MBNL1-deficient Caenorhabditis elegans
 * Wang et al. Biochem. Biophys. Res. Commun. 366 (2008) 705-709
 * Spilker et al. Neural. Dev. 7 (2012) 7
MBNL2-deficient Zebrafish
 * Machuca-Tzili et al. Dis. Model. Mech. 4 (2011) 381-392
muscleblind-deficient flies
 * Artero et al. Dev. Biol. 195 (1998) 131-143
 * Machuca-Tzili et al. Hum. Genet. 120 (2006) 487-499
 
MBNL-deficient mice
 * Kanadia et al. Science 302 (2003) 1978-1980 (Mbnl1 knock-out)
 * Lin et al. Hum. Mol. Genet. 15 (2006) 2087-2097 (Mbnl2 knock-out)
 * Hao et al. Dev. Dyn. 237 (2008) 403-410 (Mbnl2 knock-out)
 * Charizanis et al. Neuron. 75 (2012) 437-450 (Mbnl2 knock-out)
CUG-expressing mice
 * Mankodi et al. Science 289 (2000) 1769-1773 (muscle-specific)
 * Seznec et al. Hum. Mol. Genet. 10  (2001) 2717-2726 (multisystemic)
 * Wang et al. J. Clin. Invest. 117 (2007) 2802-2811 (inducible)
 * Mahadevan et al. Nat. Genet. 38 (2006) 1066-1070 (reversible)
CUG-expressing flies
 * Houseley et al. Hum. Mol. Genet. 14 (2005) 873-883
 * de Haro et al. Hum. Mol. Genet. 15 (2007) 2138-2145
 * Le Mée et al. PLoS One 3 (2008) e1466
 * Yu et al. PLoS Genet. 7 (2011) e1001340
 * Lawlor et al. Hum. Mol. Genet. 20 (2011) 3757-3768
CELF1-overexpressing mice
 * Timchenko et al. J. Biol. Chem. 279 (2004) 13129-13139 (constitutive in muscle)
 * Hao et al. Hum. Mol. Genet. 14 (2005) 1539-1547 (constitutive in muscle and heart)
 * Koshelev et al. Hum. Mol. Genet. 19 (2010) 1066-7105 (inducible)
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Fig. 2. The contribution of some transgenic animals to the understanding of the fundamental pathways of RNA toxicity in DM. Transgenic mice, Drosophila and C. elegans have been
engineered to express non-coding trinucleotide CUG repeats, directly demonstrating the toxicity of expanded RNA transcripts across a variety of tissues and species. Additional an-
imal models were generated through inactivation of MBNL proteins or the upregulation of CELF1, to show the important contribution of these two splicing regulators in the mech-
anisms that govern RNA toxicity and disease pathogenesis.
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eye degenerative phenotype [70].
The toxicity of CUG repeats has been shown to extend to other
model organisms. The expression of untranslated CUG expansions in
the body wall muscles of the nematode Caenorhabditis elegans caused
severe developmental defects in a length-dependent manner, possi-
bly recreating aspects of the congenital form of DM1 [71].
In summary, CUG repeats are toxic to a variety of model organisms
(Fig. 2) indicating commonmechanisms of RNA toxicity with harmful
effects to the cell (Table 1).
2.4. Considerations on animal models of RNA toxicity
The value of a transgenic animal model of human disease relies on
its ability to recreate molecular and phenotypic aspects of the disorder
as faithfully as possible. The generation of relevant animal models de-
mands careful thought and planning. Our past experience with DM an-
imal models has highlighted several aspects that must be considered,
guiding us through some of the choices when creating a mouse model
of toxic RNA. Firstly, the type of model: classic transgenic versus a
conditional/inducible line. In contrast to conventional transgenicmodels,
conditional or inducible models allow spatial and temporal control
of transgene expression. The inducible EpA960 [61,62] illustrates the
advantage to dissect tissue-speciﬁc disease mechanisms, over theconventional, multisystemic DM300/DMSXL mice [20]. Secondly, trans-
genic lines generated by random integration of different constructs
(e.g. different repeat lengths) must be carefully matched for transgene
copy number and expression levels to obtain comparable lines. Thirdly,
the choice of promoter to drive the expression of the transgene should
faithfully recapitulate the native expression pattern. This could be
achieved through the engineering of knock-in mice or the use of BAC
or YAC constructs that include the human promoter and regulatory
regions. Cell-speciﬁc promoters may also be considered to determine
the impact on the mutation in speciﬁc cell populations, like in HSALR
mice that speciﬁcally express untranslated CUG repeats in skeletal
muscle [21]. Fourthly, the purity of the repeatmust be considered, as in-
terruptions canmodify the disease phenotype in humans [72,73] and in
transgenic animals [74]. Fifthly, the choice of genetic background has a
profound impact on the phenotypic expression of a genetic mutation.
The neuropsychological phenotypes, in particular, are dramatically
responsive to genetic background.
The introduction of large repeats into transgenic animals is some-
times required, either to induce severe phenotypes or to study the
mechanisms of repeat instability that generate large expansions.
This adds an additional difﬁculty, since pure large repeats tend to be
dramatically unstable during the cloning steps into bacteria, with a
marked tendency to contract [75]. There are several ways around
this problem. The insertion of large genomic transgenes into BACs
1394 G. Sicot, M. Gomes-Pereira / Biochimica et Biophysica Acta 1832 (2013) 1390–1409or YACs can protect the expanded repeat from the predominant con-
traction events in bacteria and yeast. This strategy was successfully
used to generate the DM300mice [76]. Interruptions can also stabilise
the repeat and avoid repeat loss during bacterial cloning, like in
EpA960 mice [61]. Alternatively, bacteria strains and growth condi-
tions can be optimised to minimise repeat contractions and increase
the rate of expansion [77]. Finally, artiﬁcially long repeats can be cre-
ated by PCR to bypass the risk of repeat loss during bacterial ampliﬁ-
cation [78].
3. Reﬁning our understanding of RNA toxicity: Putting together
the pieces of the puzzle
Despite indirect evidence of MBNL and CELF involvement in a dis-
ease mechanism characterised by nuclear RNA retention and splicing
dysregulation, the direct role of these two protein families in disease
pathogenesis remained to be demonstrated. The generation of trans-
genicmice inactivated forMBNL1 orMBNL2 proteins, or overexpressing
CELF1 has resolved this question (Fig. 2).
3.1. Inactivation of MBNL proteins
In order to test the hypothesis that sequestration of MBNL1 by RNA
foci contributes to DM1 pathogenesis, the murine Mbnl1 gene was ge-
netically inactivated (Table 1).Mbnl1Δ3/Δ3 mice were engineered to ex-
press Mbnl1 isoforms unable to bind the CUG RNA repeats, thereby
recreating the DM1 situation, where CUG-binding isoforms are exten-
sively sequestered into ribonuclear foci and become functionally
unavailable. Mbnl1Δ3/Δ3 mice show typical DM1-associated features,
such as myotonia, dust-like cataracts [79], cardiac-conduction defects
[80], and lack of motivation and apathy in behavioural tasks [81].
These phenotypes were associated with extensive spliceopathy in
mouse skeletal muscle and heart [79], as well as brain, to a milder ex-
tent [80]. The disruption of the muscleblind homolog in ﬂies is lethal
and induces muscle defects [82], associated with splicing abnormalities
[83]. In C. elegans, CeMbl mutation causes neuromuscular junction im-
pairment, decreases synaptic density and is associated with behaviour
abnormalities [84]. These ﬁndings are consistent with a pathogenic
role of MBNL1 sequestration and loss of function in multiple tissues.
Nevertheless,Mbnl1 inactivation does not reproduce all disease features
and experimental evidence has suggested that additional proteins of
the muscleblind family play a role in the molecular mechanisms of dis-
ease pathogenesis. In addition to MBNL1, MBNL2 and MBNL3 also
colocalise with expanded DMPK and CNBP ribonuclear inclusions [44],
and possibly mediate key events in the disease cascade. Additionally,
MBNL1 loss of function in Mbnl1Δ3/Δ3 mice does not explain all the
gene expression changes detected in the HSALR line [85], suggesting
the role of additional disease intermediates. Therefore, a combinatorial
loss of function of several muscleblind-like proteins may contribute to
the disease process.
To address the involvement of MBNL2, the other major MBNL pro-
tein expressed in adult tissues, knock-out mouse and zebraﬁsh lines
were generated (Fig. 2). One of the mouse lines exhibited a normal
muscle phenotype [51], while a second line displayedmotor andmuscle
phenotypes, which included myotonic discharges, histological abnor-
malities andmildmissplicing in skeletalmuscle [86]. Themilder pheno-
type of these mice, when compared to the Mbnl1Δ3/Δ3 knock-out line,
argued against a major role of MBNL2 loss of function in muscle pathol-
ogy. In contrast, the prominent role of MBNL2 inactivation in the CNS
was recently illustrated in a third Mbnl2-deﬁcient line. These mice
showed splicing abnormalities, speciﬁcally in the CNS, in contrast to
the modest brain missplicing in Mbnl1 knock-out. In addition, Mbnl2-
deﬁcient mice displayed relevant sleep disturbances, cognitive deﬁcits
and impaired synaptic transmission [87]. These data support a tissue-
speciﬁc component of the contribution of MBNL loss-of-function to dis-
ease phenotypes:whileMBNL1 is a prevalent splicing factor and diseaseintermediate in skeletal muscle, MBNL2 plays a predominant role in the
CNS. The determinant role of MBNL2 has been corroborated by the de-
velopmental abnormalities detected in zebraﬁsh followingmbnl2 inac-
tivation [88] (Table 1).
The involvement ofMBNL3 inDM is less clear, and no animalmodels
have been generated to address this question. MBNL3 is mainly ex-
pressed in embryonic tissues [89], and although upregulation of this
protein was detected in DM1 skeletal muscle [90], its contribution to
pathogenesis has not been determined.
3.2. CELF1 overexpression
The inactivation ofMBNL proteins fails to recreate important DMphe-
notypes, such asmuscleweakness, suggesting a role for additional disease
intermediates. To investigate the contribution of CELF1 upregulation to
disease pathogenesis, overexpressing mice were generated (Fig. 2). The
constitutive overexpression of CELF1, either ubiquitously or in muscle,
resulted in severe developmentally phenotypes, possibly mimicking cer-
tain aspects of the congenital form of DM1 [91,92]. To overcome the high
mortality of these lines and to investigate the tissue-speciﬁc conse-
quences of CELF1 upregulation, an inducible CELF1-overexpressing line
was generated. Tissue-speciﬁc CELF1 overexpression in either skeletal
muscle or heart of adult mice induced DM1-characteristic phenotypes
and was associated with themissplicing of CELF1-dependent target tran-
scripts [93,94], indicating that CELF1 upregulation is sufﬁcient to repro-
duce some features of DM-associated RNA toxicity (missplicing) and
physiological phenotypes (myopathy and cardiomyopathy) (Table 1).
CELF2 upregulation has been reported in DM1 human brains
[60,95] and associated with missplicing of MAPT/Tau [95]. Further
studies are required to determine the implications of this ﬁnding to
the neuropsychological manifestations of DM1.
3.3. Dysregulation of a developmental programme of alternative splicing
induces DM relevant disease features
The generation of transgenic mouse models expressing altered levels
of MBNL and CELF proteins, demonstrated the central role of these two
antagonistic families of splicing regulators in DMmolecular pathogenesis.
Proper splicing of MBNL- and CELF-dependent transcripts depends on a
ﬁne equilibrium between these two splicing regulators. MBNL1 intracel-
lular distribution and CELF1 steady-state levels are developmentally reg-
ulated in mouse. While MBNL1 translocates from a predominantly
cytoplasmic location in the embryo to a predominantly nucleoplasmic lo-
cation in adult animals [51], CELF1 steady-state levels decrease in adult
heart and skeletal muscles when compared to newborn tissues [96,97].
The expression of toxic CUG RNA repeats affects these two families of
splicing regulators through the sequestration of MBNL proteins in the
nucleus [43,44], and PKC-mediated hyperphosphorylation of CELF1 and
subsequent protein stabilisation and upregulation [96]. The MBNL1 re-
cruitment to nuclear foci and the increased levels of CELF1mimic the em-
bryonic situation, resulting in aberrant expression of embryonic splicing
proﬁles in adult skeletal muscle and heart. However, direct evidence to
demonstrate that missplicing is causative of disease, rather than a down-
stream epiphenomenon parallel to the pathogenic pathway was lacking.
The pathogenic role of missplicing in DM1was tested directly by thema-
nipulation of theHSALRmousemodel expressing non-coding CUG repeats
in the skeletal muscle. Chloride channel Clcn1 transcripts undergo many
splicing abnormalities in the skeletal muscle of adult HSALR mice, such
as the retention of embryonic exon 7a [21,48,55]. Misspliced Clcn1
transcripts can either undergo accelerated non-sense mediated decay or
encode truncated non-functional chloride channels, resulting in de-
creased CLCN1 immunostaining in the sarcolemma [55] and dramatic
70% reduction in transmembrane CLCN1 channel currents in isolated
muscle ﬁbres [98,99]. The injection and electroporation of a morpholino
antisense oligonucleotide into the tibialis anterior muscle of HSALR
mice reversed Clcn1 missplicing, upregulated sarcolemmal expression,
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discharges [100], providing direct evidence for the causative role of
missplicing in myotonia development. More recently, muscle weakness
in DM1 and DM2 was associated with bridging integrator 1 (BIN1)
missplicing. BIN1 is a lipid-binding protein that is involved in the bio-
genesis of the T tubule network in muscle and in the regulation of the
excitation–contraction coupling. Inactivation ofMBNL1 by foci sequestra-
tion induces BIN1 exon 11 skipping and deregulates the lipid-binding
activity of BIN1 and contributes to muscle weakness. The link was
shown by an exon-skipping strategy designed to force the exclusion of
exon 11 in the skeletal muscle of wild-type mice, which resulted in mor-
phological changes and a decrease in speciﬁc muscle strength. Similar to
the role of CLCN1 and BIN1 missplicing in causing myotonia and muscle
weakness, respectively, the missplicing of the insulin receptor (INSR)
most likely accounts for theDM-associated insulin resistance, since it pro-
duces an isoformwith lower signalling capacity [49,50]. Other transcripts
misspliced in heart (e.g. TNNT2) or in brain (e.g. NMDA receptor 1 or
microtubule-associated Tau protein) may contribute to tissue-speciﬁc
disease manifestations. However, direct evidence of a cause–effect rela-
tionship is still missing.
Importantly, dysregulated splicing can also be a secondary conse-
quence of tissue degeneration. To illustrate the confounding effect of
muscle regeneration, induced and genetic non-DM models of muscle
injury shared missplicing events with established DM1 models, in as-
sociation with changes in the expression of MBNL and CELF proteins
[101]. These results suggest that splicing regulators respond not
only to toxic CUG RNA repeats, but also to cycles of muscle damage
and subsequent regeneration, to increase the expression of neonatal
splicing isoforms. Although a primary consequence of RNA toxicity,
dysregulation of alternative splicing in DM can also be a consequence
of muscle regeneration.
4. New insights into DM molecular pathogenesis and RNA toxicity
The working model of RNA toxicity has been recently challenged
by experimental evidence that shows directly that molecular patho-
genesis goes beyond spliceopathy.
4.1. Two protein families, many consequences to the cell: altered RNA ex-
pression, metabolism and localisation
Microarray studies have revealed abnormal gene expression in mus-
cle biopsies from DM1 and DM2 patients [102–104]. The comparative
study of DM mouse models by expression microarrays revealed that
60–70% of these changes could be explained by loss of MBNL1 [85,105].
Besides an important role in splicing regulation, MBNL1 and CELF1 can
control gene expression, possibly operating at different levels (Fig. 1).
Both MBNL1 and CELF1 can bind directly the 3′UTR of target transcripts
to regulate mRNA decay [106]. In addition, MBNL1 participates in the
regulation of the biogenesis of miRNA species, having an impact on the
expression of their targets [107]. As a result, MBNL1 sequestration likely
contributes, at least partly, to miRNA dysregulation in DM1 and DM2
muscle biopsies [107–110], as well as in CUG-expressing transgenic
ﬂies [111]. At the post-transcriptional level, CELF1 increases the transla-
tion of some downstream transcripts [91,112].
MBNL proteins can also have a cytoplasmic role inmRNA localisation,
as illustrated by the subcellular relocalisation of MBNL targets in myo-
blasts and ﬂies depleted of MBNL proteins. These results predict an
impact of DM and MBNL inactivation on cellular structures that are par-
ticularly sensitive to mRNA localisation (such as neuronal synapses or
the neuromuscular junction) [113]. Previously, MBNL2 was found to be
required for the correct localisation of integrin α3 protein to the adhe-
sion complexes [114]. However, the relevance of these ﬁndings to DM
pathogenesis remains to be explored.
In any case, any deviation from the ﬁne balance between the
MBNL and CELF protein families will affect, not only the alternativesplicing of target transcripts but also gene expression, protein levels,
as well as RNA and protein localisation (Fig. 1).
4.2. MBNL and CELF joined by other partners in crime
DM molecular pathogenesis is not limited to the dysregulation of
MBNL and CELF proteins and is most likely mediated by additional dis-
ease intermediates, as illustrated by evidencemostly gathered fromDM
cell models (Fig. 1). Firstly, hnRNP H levels are elevated in DM1 myo-
blasts, possibly contributing to abnormal splicing [115]. Secondly, the
aberrant cytoplasmic localisation of SPEN homolog, transcriptional reg-
ulator (SPEN/SHARP) in DM1 cells functionally inactivates this tran-
scription factor and can explain the downregulation of transcripts,
independently of MBNL1 inactivation or CELF1 upregulation [116].
Thirdly, the RNA DEAD box helicase 5 (DDX5/p68) partially localises
with RNA foci in transfected cells, and shows amodest effect on the reg-
ulation of the splicing events affected in DM1 [117]. Fourthly, expanded
RNAs bind and sequester SP1 and retinoic acid receptor γ (RARγ) in
DM1 cells, affecting gene expression through the redistribution and de-
pletion of these transcription factors from active chromatin [118].
Fifthly, NK homoeobox 5 (NKX2-5) is transcriptionally activated in
DM1, contributing to changes in gene expression in skeletal and cardiac
muscles [119].
Transgenic ﬂies have also been particularly useful in the identiﬁca-
tion of cellular components altered by the CTG expansion, as well as
genetic modiﬁers of CUG toxicity, helping to expand our understand-
ing of an increasing number of disease intermediates in DM patho-
genesis [120,121].
Mimicking the abnormal expression and/or mislocalisation of these
proteins in animalmodels is required to decipher the underlyingmech-
anisms and the impact of these changes in various tissues, their implica-
tions to disease manifestations and their therapeutic potential.
4.3. Shufﬂing the cards: RNA toxicity and polyglutamine toxicity are not
mutually exclusive
Following the discovery of the pervasive transcription, a CAG-
containing DMPK antisense transcript was identiﬁed emanating from
the DM1 locus [122]. Bidirectional transcription across repeat expan-
sions is a recurrent feature in some trinucleotide repeat loci [123], and
results in the production ofmultiple toxic repeat-containing transcripts,
and in a signiﬁcantly higher pathogenic potential of microsatellite ex-
pansions. The role of antisense DMPK transcripts in disease pathogene-
sis is still unclear. It was initially suggested that antisense RNA acts as a
trans-modiﬁer of chromatin environment and gene expression, through
the generation of 21-nucleotide fragments [122]. Insulator CTCF binding
sites were identiﬁed ﬂanking the CTG repeat in the DM1 locus, possibly
regulating chromatin insulation and transcription [124]. Large congen-
ital CTG repeat expansions were associated with loss of CTCF binding,
spreading of the region of antisense transcription, histone modiﬁca-
tions, heterochromatinisation and CpGmethylation [122]. Suchmodiﬁ-
cations may lead to the loss of insulator activity and high DMPK
expression levels in late embryogenesis, when SIX5 expression is also
high. The subsequent accumulation of abnormally increased levels of
DMPK transcripts may contribute to the earlier and severe congenital
phenotype. Identiﬁcation of antisense transcripts and CTCF binding
sites ﬂanking trinucleotide repeats at other disease loci suggests that
certain epigenetic features and chromatin regulatory pathways de-
scribed at the DM1 locus might be shared with other repeat sequences
in the genome [123,125,126]. The importance of epigenetic regulation
at repeat loci transcribed in both directions was illustrated through
the generation of transgenic mice of SCA7, a dominant neurodegenera-
tive disorder caused by the expansion of a polyglutamine-encoding CAG
trinucleotide expansion. Themutation of the CTCF binding sitesﬂanking
the repeat resulted in loss of antisense transcription, and concomitant
cis derepression of an alternative sense transcript, in association with
Table 1
Main animal models of toxic RNA diseases, their genetic features, phenotypes and implications to the understanding of disease biology.
Disease Strategy Animal model Main phenotypes Main molecular features Implications References
Species Genetic features
DM1 CUG
expressing
lines
Mouse Expression of untranslated CTG expansion
in skeletal muscle
Myotonia and mild myopathy RNA foci; MBNL sequestration;
missplicing
Non-coding CUG repeats are toxic in muscle,
independent of genomic context
[21]
Multisystemic expression of expanded
human DMPK transcripts
Mild myotonia; progressive muscle weakness;
abnormal glucose metabolism; tauopathy;
synaptic dysfunction
RNA foci; MBNL sequestration;
mild missplicing
Non-coding CUG repeats are deleterious to
multiple tissue and organ systems
[20,57–60]
Inducible expression of untranslated CTG
expansions within DMPK exon 15
Myotonia; progressive muscle wasting; cardiac
conduction defects; histopathology
RNA foci; MBNL sequestration;
CELF1 upregulation; missplicing
Tissue-speciﬁc toxicity of CUG repeats in skel-
etal muscle and heart
[61,62]
Inducible and reversible overexpression of
short CTG repeats
Myotonia; cardiac conduction defects Histopathology; CELF1
upregulation; NKX2–5
upregulation
Reversibility of RNA toxicity and DM1
phenotypes
[178]
Drosophila Expression of untranslated (CTG)160
expansions
No detectable pathological phenotype RNA foci; MBNL sequestration RNA foci are not sufﬁcient to elicit pathology [67]
Expression of untranslated and interrupted
(CTG)480 expansions
Eye and muscle degeneration; muscle wasting RNA foci; missplicing MBNL1 and CELF1 mediate pathology in ﬂies.
Identiﬁcation of chemical and genetic modiﬁers
of CUG toxicity.
[68,121]
Inducible expression of untranslated CTG
expansions
Eye neurodegeneration; reduced viability RNA foci Role of genomic context in toxicity of CUG
repeats
[70]
Expression of untranslated CTG and CAG
complementary expansions
Eye neurodegeneration RNA foci; missplicing Enhancement of CUG toxicity by siRNA
pathways
[69]
Eye neurodegeneration; movement disorder miRNA dysregulation Role of Dicer-mediated pathways in disease
pathogenesis
[131]
Caenorhabditis
elegans
Expression of untranslated CTG repeat
expansions
High mortality; growth retardation; defective
muscle development
Not reported CUG RNA repeats ate toxic in C. elegans and
disturb development
[71]
Expression of untranslated CAG and CTG
expansions
Shortened life span; reduced motility RNA foci; MBNL sequestration Toxicity of CUG and CAG RNA repeats in C.
elegans is mediated by MBNL1
[198]
Mbnl1 KO Mouse Absence of CUG-binding MBNL isoforms Myotonia; cataracts; apathy and motivational
deﬁcits; histopathology
Missplicing MBNL1 inactivation induces DM phenotypes [79,81]
Caenorhabditis
elegans
Disruption of muscleblind Motility phenotypes; impaired neuromuscular
junction
Not reported Regulatory role of MBNL1 in synapse formation [84]
Drosophila Disruption of muscleblind Muscle defects; lethality; histopathology Missplicing Role of muscleblind in muscle development
and physiology
[82,83]
Mbnl2 KO Mouse Disruption of the second intron of the
mouse Mbnl2 gene by insertion of
Neo-LacZ gene trap
Myotonia; myopathy Missplicing; histopathology Controversial role of MBNL2 inactivation in DM
muscle pathology.
[86]
Normal muscle phenotype Normal phenotype [51]
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Disease
Strategy Animal model Main phenotypes Main molecular features Implications References
Species Genetic features
Gene disruption by insertion of a retroviral
GT vector in the fourth intron of the mouse
Mbnl2 gene
Disruption ofMbnl2 exon 2 by homologous
recombination
Sleep abnormalities; cognitive deﬁcits; seizure
susceptibility
Missplicing in brain MBNL2 loss of function induces phenotypes in
CNS
[87]
Zebraﬁsh Disruption of mbnl2 gene Developmental abnormalities in eyes, heart,
brain and muscle; histopathology.
Missplicing Role of MBNL2 in pathology and development [88]
CELF1
overexpression
Mouse Constitutive CELF1 overexpression in
skeletal muscle
Impaired muscle development; high mortality Histopathology CELF1 upregulation causes developmental
abnormalities (contribution to congenital
DM1?)
[91]
CELF1 overexpression in skeletal
muscle and heart
Neonatal mortality; histopathology; impaired
development
Missplicing [92]
Conditional CELF1 overexpression Cardiac hypertrophy; cardiomyopathy; mouse
lethality
Missplicing CELF1 overexpression in skeletal and heart is
sufﬁcient to recreate some important disease
phenotypes
[93,94]
FXTAS CGG
expressing
lines
Drosophila Expression of untranslated CGG
expansions
Ubiquitous expression: lethal
Neuronal expression: eye neurodegeneration
Cytoplasmic and nuclear
ubiquitin-positive inclusion;
Purα sequestration
CGG RNA repeats are toxic and mediate FXTAS
pathogenesis. Identiﬁcation of disease
modiﬁers.
[140,144]
Mouse Expression of untranslated CGG
expansions
Learning and motors deﬁcits; histopathology Intranuclear inclusions in brain [141,143]
SCA8 CUG
expressing
lines
Drosophila Expression of non-coding CUG ATXN8 RNA Eye neurodegeneration Sequestration of Staufen Non-coding CUG SCA8 repeats are toxic. Iden-
tiﬁcation of disease modiﬁers.
[152]
CAG and CUG
expressing
lines
Mouse Expression of full-length human ATXN8
transcripts (sense and antisense)
Neurological phenotype; histopathology RNA foci; MBNL1 sequestration;
missplicing; dysregulation of
CELF1 targets
Role of polyglutamine stretches and toxic RNA
and in SCA8
[26,153]
HDL2 CAG and CUG
expressing
lines
Mouse Expression of both strands of an expanded
JPH3 gene
Motor deﬁcits; neurodegeneration RNA foci; MBNL1 and CBP se-
questration; polyglutamine
inclusions
Role of polyglutamine stretches and toxic RNA
and in HDL2
[157]
SCA10 AUUCU RNA
expressing
lines
Mouse Expression of an intronic ATTCT expansion
in ATXN10 gene
PKC∂ accumulation in mitochondria RNA foci; hnRNP K sequestration Non-coding AUUCU repeats are toxic, indepen-
dent of genomic context
[27]
Mouse Expression of a ATTCT expansion in 3′UTR
of an unrelated gene
Locomotive dysfunction; seizures;
neurodegeneration; PKC∂ accumulation in
mitochondria
RNA foci; hnRNP K sequestration [161]
SCA12 Ppp2r2b
overexpression
Drosophila Overexpression of the Bß2 isoform and
Drosophila homolog
Shortened life span; neurodegeneration;
autophagy
Increased oxidative stress Non-coding intronic CAG repeats in Bß2 iso-
form are toxic
[166]
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highlight the important of epigenetic regulation in the control of gene
expression and disease pathology associated with repeat loci bidirec-
tionally transcribed.
Today, we know that antisense DMPK transcripts accumulate in
CAG-containing RNA foci in DM1 tissues and in DMSXL transgenic
mice [59], possibly triggering additional pathways of toxicity. This hy-
pothesis is corroborated by the muscle histopathology and behav-
ioural phenotypes developed by mice expressing untranslated CAG
repeats in an unrelated context [128]. The absence of polyglutamine
tracts in these models clearly implicates a component of RNA toxicity
in CAG expansion disorders, previously considered as exclusively me-
diated by proteotoxicity. The co-localisation of MBNL1 with CAG-
containing foci in transfected cells [129], in mice expressing non-
coding CAG repeats [128] and in DM1 human tissues [59], predicts a
unifying mechanisms for CUG and CAG RNA toxicity grounded on
MBNL1 sequestration and loss of function. In support of this view,
the splicing of MBNL1-dependent targets is dysregulated in HD and
SCA3 ﬁbroblasts [130], extending the impact of spliceopathy to CAG
repeat expansion diseases.
Interestingly, the co-expression of untranslated CUG and CAG RNA
repeats has a synergistic effect and aggravates the phenotypes of ﬂies
expressing one single type of repeats [69,131,132]. The enhanced toxic-
ity is mediated by the small interference RNA (siRNA) machinery,
which generates 21-nucleotide fragments that target and reduce the
levels of other repeat-containing target transcripts in the cell [69,131].
Repeat containing siRNA species can also be generated by the cleavage
of single-stranded CUG- and CAG-containing transcripts folded into im-
perfect hairpins [133,134]. The expression of sense and antisense DMPK
transcripts in DM1 cells may therefore activate siRNA biogenesis
through similar mechanisms, generating repeat-containing siRNA that
will contribute to gene expression dysregulation. The siRNA targets as
well as their distribution and contribution to DM pathogenesis can be
studied in transgenic mice expressing expanded repeat-containing
transcripts.
These ﬁndings have extended the role of RNA toxicity to other dis-
eases. However, given the overwhelming evidence of the deleterious ef-
fect of polyglutamine peptides [11], it remains unclearwhether CAGRNA
toxicity contributes signiﬁcantly to the pathogenesis of polyglutamine
expansion disorders.
5. Pushing the boundaries of RNA toxicity: Other toxic RNA diseases
Although setting the paradigm of toxic RNA diseases, DM is no
longer alone — evidence of RNA toxicity has been found in other
human conditions. Transgenic animal models have provided crucial
evidence of toxic RNA mechanisms in these disorders, and revealed
similarities as well as differences with the mechanisms operating in
DM (Table 1, Fig. 3).
5.1. Fragile X-associated tremor/ataxia syndrome (FXTAS)
Fragile X syndrome is the most common inherited form of mental
retardation, and it has been associated with a CGG repeat expansion
in the 5′UTR of the fragile X mental retardation 1 (FMR1) gene. While
the non-affected population has up to 55 repeats, fragile X patients
carry more than 200 CGG repeats [1,4,135]. Elderly individuals carrying
premutations of 55–200 CGG develop a progressive neurodegenerative
disorder called fragile X-associated tremor/ataxia syndrome (FXTAS),
mainly characterised by cerebellar gait ataxia and intention tremor,
among other neurological symptoms [136]. Although caused by muta-
tions in the same locus, fragile X syndrome and FXTAS are mediated
by distinct disease mechanisms: FMR1 loss of function in fragile X syn-
drome, and toxic RNA gain of function in FXTAS.
The ﬁrst evidence that FXTAS is mediated by toxic CGG RNA re-
peats came from the observation that FMR1 mRNA levels areincreased in individuals carrying 55–200 CGG repeats [137], and
from the accumulation of expanded CGG-containing mRNA tran-
scripts in intranuclear inclusions in brain [138,139]. But the toxicity
of CGG RNA repeats was ﬁrst demonstrated in transgenic ﬂies. The
ubiquitous or neuronal expression of untranslated (CGG)90 in Dro-
sophila was lethal, while expression in the retina caused a neurode-
generative eye phenotype in association with the accumulation of
cytoplasmic and nuclear inclusions positive for ubiquitin, Hsp70 and
proteasome components [140]. Similarly, mice expressing a CGG re-
peat expansion, either in the context of the murine Fmr1 gene or in
the 5′UTR of an unrelated gene demonstrated that these RNA repeats
were sufﬁcient to cause learning and neuromotor deﬁcits [141,142],
in association with increased Fmr1 mRNA levels and intranuclear in-
clusions in brain [141,143] (Table 1).
A number of studies have focused on the identiﬁcation of proteins
that interact with the expanded CGG RNA repeats, which could mediate
trans-dominant RNA toxicity in this condition. Purine-rich element bind-
ing protein A (PURA/Purα) interacts with CGG repeats and colocalises
with CGG-containing RNA foci in FXTAS brain tissue [144]. The neurolog-
ical phenotype of Purα knock-out mice [145] and the rescuing of the
phenotype of CGG transgenic ﬂies by Purα overexpression [144] further
supported a trans-actingmechanism of RNA toxicity. Other diseasemod-
iﬁers have been identiﬁed, through their ability to suppress the eye neu-
rodegenerative phenotype of CGG transgenic ﬂies, such as hnRNP A2/B1,
CELF1, Hsp70 and several histone deacetylases (HDACs) [140,144,146,
147]. More than 20 proteins co-localise with FXTAS intranuclear inclu-
sions, such as the splicing regulators Sam68 (KH domain containing,
RNA binding, signal transduction associated 1, KHDRBS1) and MBNL1
[148,149] (Fig. 3). Protein sequestration inactivates Sam68, resulting
in dysregulation of Sam68-dependent splicing [149], but it is unknown
whether Sam68-regulated splicing events are relevant to disease symp-
toms. Future studies are also needed to elucidate the contribution of
other abnormal RNA–protein interactions to cell dysfunction and dis-
ease phenotypes in FXTAS.
Similar to DM, FXTAS disease mechanisms involve nuclear accumu-
lation of toxic RNA transcripts, protein sequestration of splicing regula-
tors and subsequent spliceopathy. However, the protecting effect of
CELF1 overexpression in (CGG)90 transgenic ﬂies suggests fundamental
differences between DM1 and FXTAS diseasemechanisms.Moreover, in
contrast to CUG and CAG repeats, the co-expression of CGG and GCC
complementary repeats suppressed the individual toxicities of the re-
peats [150].
5.2. Spinocerebellar ataxia type 8 (SCA8)
SCA8 is a late-onset disorder characterised by a slow and progres-
sive form of cerebellar ataxia and neurodegeneration. SCA8 is caused
by a CTG·CAG repeat expansion transcribed in both directions, pro-
ducing a CUG ATXN8OS transcript and a CAG ATXN8 transcript [151].
As in DM1, the CUG RNA accumulates in nuclear foci, sequesters
MBNL proteins and triggers splicing abnormalities, notably in the cere-
bellum [26]. In addition, putative CELF1 targets appear to be abnormally
expressed in SCA8 [26], but it remains to be shownwhether CELF1 itself
is affected in this condition (Fig. 3). Evidence of the toxic role of SCA8
transcripts was also reported in Drosophila. The expression of short
and expanded non-coding CUG-containing SCA8 transcripts in the pho-
toreceptor neurons results in progressive neurodegeneration of the ret-
ina [152]. Consistent with a mechanism mediated by toxic RNAs, a
genetic screening of disease modiﬁers in Drosophila identiﬁed several
RNA binding proteins, includingmuscleblind and staufen [152] (Table 1).
The translation of the CAG ATXN8 RNA produces a nearly pure
polyglutamine tract that accumulates in intranuclear protein inclu-
sions, like in many other SCAs [153]. Transgenic mice expressing a
SCA8 (CTG·CAG)118 in both directions, recapitulate capital disease
features, including progressive neurological phenotypes and cerebellar
neurodegeneration, in association with intranuclear CUG-containing
DM
MBNL
MBNL
MBNL
CELF1
CELF1
CELF1
HD
MBNL1
MBNL1
• Nuclear RNA foci
• MBNL1 sequestration
• CELF1 target 
  dysregulation
• Missplicing
• Nuclear and cytoplasmic
  RNA foci
• hnRNP K sequestration
• Missplicing
• Nuclear RNA foci
• MBNL sequestration
• CELF1 upregulation (DM1)
• Missplicing
• Nuclear RNA foci
• MBNL1 sequestration
• Missplicing
SCA8
CELF1 ?CELF1 ?
MBNL1
MBNL1
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Fig. 3. Comparative schematic representation of the mechanisms of RNA toxicity operating in DM, FXTAS, SCA8, SCA10 and polyglutamine expansion diseases. The accumulation of
expanded transcripts (mostly in ribonuclear aggregates or foci) and the functional dysregulation of RNA-binding proteins appear to be a common feature of many RNA toxic dis-
eases. Most proteins are functionally disturbed by sequestration into RNA foci resulting in splicing dysregulation — a common event in toxic RNA diseases. Some proteins appear to
be involved in multiple disease mechanisms, such as the members of the MBNL and CELF protein families. CELF1 (and CELF2) is upregulated in DM1, and it is also likely to be in-
volved in FXTAS and SCA8 disease mechanisms.
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reduced MBNL1 protein levels, resulting from the inactivation of one
Mbnl1 allele, accentuated rotarod deﬁcits in SCA8 transgenic mice,
suggesting that the CUG-containing SCA8 transcripts affect MBNL1-
regulated pathways in the brain [26]. SCA8 mice provided deﬁnitive ev-
idence that bothmechanisms of RNA and protein toxicity can operate in
a single neurological disease, as a result of the production of sense and
antisense transcripts.
Protein toxicity in SCA8 does not seem to be limited to the accumula-
tion of polyglutamine tracts, and may result from non-orthodox trans-
lational mechanisms. This was ﬁrst detected when investigating the
contribution of ataxin 8 protein to SCA8 pathogenesis, through the trans-
fection of expanded CAG-containing ATXN8OS constructs lacking the ATG
initiation codon into cultured cells. Unexpectedly, the mutation of the
ATG codon did not prevent translation of the expanded construct in the
three possible reading frames, generating polyglutamine, polyserine and
polyalanine homopolymers through unconventional repeat-associated
non-ATG-mediated (RAN) translation [154]. The accumulation of RAN-
translated proteins was conﬁrmed in the brain of SCA8 patients and
transgenic mice [154]. The involvement of this mechanism was investi-
gated in DM1, resulting in the detection of a novel polyglutamine peptide
in relevant tissues from DM1 patients and DMSXL transgenic mice [154],
presumably resulting from the translation of the CAG-containing anti-
sense DMPK transcripts. RAN translation was shown to occur in other
disease-relevant sequence contexts in cell culture, but it has not been
conﬁrmed yet in human patient samples or in transgenic models of the
disease. Despite some evidence of apoptosis in response to RAN transla-
tion, we still do not know the frequency and contribution of these pep-
tides to disease pathogenesis. The validation of RAN translation in other
human diseases and its implications to cell dysfunction and disease path-
ogenesis could change our understanding of trinucleotide repeat expan-
sion disorders.5.3. Huntington-disease like 2 (HDL2)
HDL2 is a neurodegenerative disorder clinically very similar to HD,
and characterised by chorea, dystonia, psychiatric manifestations and
dementia. Pathologically, HDL2 brains accumulate ubiquitin-positive
intranuclear inclusions, suggesting HD-like disease mechanisms me-
diated by toxic polyglutamines [155]. HDL2 is caused by a CTG·CAG
repeat expansion mutation in the junctophilin-3 (JPH3) gene that is
transcribed in both senses to generate CUG- and CAG-containing
transcripts [156]. Depending on the alternative splicing, the CUGrepeat of the sense JPH3 transcript can either encode a polyalanine
or a polyleucine tract, or even be placed within the 3′UTR of the tran-
script [156].
The existence of expanded CUG repeats hinted at mechanisms of
RNA toxicity in HDL2. In favour of this hypothesis, nuclear RNA foci
were detected in neurons of HDL2 patients, co-localising with MBNL1
[31]. Like in DM1, CELF1 was not present in HDL2 RNA foci, but this
does not exclude a role of abnormal CELF1 stability or localisation in
this condition (Fig. 3). The transfection of mutant CUG-containing
JPH3 transcripts (genetically modiﬁed to prevent transcription) dysre-
gulated MBNL1-dependent alternative splicing in cultured cells. The
toxicity of expanded CUG-containing JPH3 transcripts was conﬁrmed
in BAC transgenic mice, which exhibited motor and neuropathological
phenotypes, associated with the accumulation of MBNL1-containing
RNA foci [157] (Table 1). In addition, nuclear retention of JPH3 tran-
scripts can also affect protein levels and contribute to disease pathogen-
esis. In fact, JPH3 loss of function was found deleterious in knock-out
mice, causing relevant progressive motor deﬁcits [158].
Polyglutamine aggregates accumulate in HDL2 mice, co-localise
with ubiquitin and are independent of RNA foci, strongly suggesting
a pathogenic role for a novel antisense CAG-containing JPH3 tran-
script that emanates from the HDL2 locus [157,158]. In further sup-
port of polyglutamine-mediated mechanisms, targeted silencing of
the CUG-containing JPH3 sense transcript in HDL2 transgenic mice
rescued neurodegeneration but did not abrogate motor deﬁcits or
neuropathology [157], indicating that the expanded polyglutamine
protein is sufﬁcient to induce certain HDL2 features.
In summary, HDL2 mice provided evidence of a multi-component
pathogenic mechanism, involving CUG-mediated spliceopathy, JPH3
loss of function through nuclear RNA retention, and polyglutamine
toxicity. Comparative studies of the pathogenic pathways shared be-
tween HDL2, DM and HD may provide insight into unifying mecha-
nisms underlying these disorders.5.4. Spinocerebellar ataxia type 10 (SCA10)
MBNL sequestration into ribonuclear inclusions is a shared event
across the molecular mechanisms of DM, FXTAS, SCA8 and HDL2
(Fig. 3). However other toxic RNA diseases that show RNA foci accu-
mulation and missplicing involve abnormal nuclear sequestration of
different RNA-binding proteins.
SCA10 is a neurodegenerative disease, characterised by progressive
cerebellar ataxia and seizures. SCA10 patients carry a non-coding
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whose function is not fully understood [159]. The expanded ATXN10
is transcribed, spliced and translated normally. In addition,mice hetero-
zygous for the Atxn10deﬁciency have a normal phenotype, demonstrat-
ing that haploinsufﬁciency does not play a major role in disease
pathogenesis [160]. Instead, the intronic localisation of the repeat and
the accumulation of AUUCU-containing ATXN10 transcripts in the nu-
cleus and cytoplasm of SCA10 ﬁbroblasts [27] are consistent with a
toxic gain of function. The toxicity of the SCA10RNA repeatwas demon-
strated through the generation of independent transgenic mouse lines
expressing AUUCU expansions within an intron or within the 3′UTR of
unrelated genes (Table 1). Both mouse models exhibited nuclear and
cytoplasmic RNA foci accumulation [27,161]. The 3′UTR model, in
particular, developed an ataxic and epileptic phenotype resembling
SCA10 disease symptoms [161]. hnRNP K was found to bind AUUCU re-
peats in vitro and to co-localise with SCA10 RNA foci in SCA10 human
ﬁbroblasts and transgenic mouse brains [27,161]. hnRNP K sequestra-
tion resulted in decreased protein activity and missplicing of hnRNP
K-regulated transcripts [27] (Fig. 3). In addition, the abnormal interaction
of hnRNPKwith the expanded repeat inducedPKC∂ translocation into the
mitochondria, activation of apoptosis in transfected neuroblastoma cell
lines [27] and it is associated with neuronal loss in transgenic mouse
brains [161]. Both transgenic lines conﬁrmed that expanded SCA10 re-
peats triggered pathogenic eventsmediated by toxic AUUCURNA repeats,
regardless of the location of the expansion within the transgene. Never-
theless, some important questions require further investigation. The con-
tribution of hnRNP K loss of function to the SCA10 phenotype might be
addressed through the generation of hnRNP K-deﬁcient mice, and the
comparative study with the AUUCU-expressing lines.
Additional mouse lines expressing the AUUCU repeat expansion in
the mouse or human genomic context might prove useful to identify
disease intermediates and to elucidate the biological pathways affect-
ed by the SCA10 expansion mutation. Interestingly, the pan-neuronal
expression of untranslated AUUCU expanded repeats in Drosophila
elicits a number of transcriptional changes that are also found in ﬂy
lines expressing toxic CUG and CAG repeats [162]. These results sug-
gest some degree of overlapping in the downstream mechanisms of
disease triggered by different toxic RNA repeats.
5.5. Spinocerebellar ataxia type 12 (SCA12)
Circumstantial data support RNA-mediated pathogenesis in other
human diseases, but relevant animal models have not yet provided
deﬁnitive evidence of toxic RNA gain of function.
SCA12 patients exhibit heterogeneous clinical manifestations, in-
cluding typical ataxia, prominent action tremor of the upper limbs, par-
kinsonism, psychiatric disorders and dementia in patients with a long
disease-course [163]. The disease is caused by a CAG trinucleotide re-
peat expansion in the 5′UTR of the PPP2R2B (protein phosphatase 2, reg-
ulatory subunit B, beta) gene, which has multiple alternative sites of
transcription initiation and alternative exons [164]. The CAG repeat
can be located just upstream of the transcriptional start site of the Bß1
transcript, or within the ﬁrst intron of the Bß2 splicing variant [163].
The expansion increases the expression of the Bß1 variant [165], but
the impact of the upregulation of this isoform is not known. In contrast,
the overexpression of the CAG-containing Bß2 isoform in Drosophila
causes mitochondrial dysfunction, oxidative stress and neuronal death
[166] (Table 1). Since it is not known whether Bß2 expression levels
are changed in SCA12, the implications of these ﬁndings to the human
pathology remain elusive. Nonetheless, the toxic effect of the intronic
CAG repeat in this isoform is compatible with a toxic RNA gain of
function. It remains to be investigated whether expanded transcripts
accumulate in SCA12 cells and disturb RNA-binding proteins through
abnormal interactions. Relevant animal models carrying the SCA12
CAG repeat expansion within its natural genomic context must be gen-
erated to understand the molecular basis of this disorder.5.6. Spinocerebellar ataxia type 31 (SCA31)
SCA31 is a pure cerebellar ataxia, affecting primarily Purkinje cells.
The disease is associatedwith the insertion of a complex pentanucleotide
repeat insertion containing a (TGGAA)n sequence [29]. The TGGAA
repeat is located in the introns of two genes transcribed in opposite
directions: the thymidine kinase 2 (TK2) and the brain expressed, associat-
ed with Nedd4 (BEAN) genes. The repeat insertion does not affect the ex-
pression or the splicing of these genes, but in situ hybridisation revealed
nuclear accumulation of UGGAA-containing BEAN transcripts in RNA foci
[29]. In addition, UGGAA RNA repeats bind serine/arginine-rich splicing
factors 1 and 9 (SRSF1 and SRSF9) in vitro, possibly perturbing RNA me-
tabolism further downstream [29]. Although there is no animalmodel to
demonstrate the trans-acting toxicity of the UGGAA RNA repeats in
SCA31, indirect evidence points in that direction. The overexpression of
the non-coding hsrωRNA (rich in UGGAA repeat sequences) exacerbates
neurodegeneration in a ﬂy model of polyglutamine disease [167], and
suggests a deleterious role of the UGGAA repeats. In further support of
RNA toxicity, inactivation of the SRSF1 and SRSF9 homologues in
C. elegans, Drosophila and mouse induces neuronal cell death, abnormal
development and early mortality [168–170].
The generation of animal models is essential to experimentally ad-
dress the sequence of events in SCA31 pathogenesis, and the toxic
role of UGGAA repeats.5.7. Spinocerebellar ataxia type 36 (SCA36)
SCA36 is a slowly progressive cerebellar ataxia with characteristic
motor neuron involvement [171]. The disease-causing mutation was
mapped to an intronic expansion of a GGCCTG hexanucleotide repeat
in the ﬁrst intron of the NOP56 ribonucleoprotein gene, a component
of the splicing machinery [30]. The repeat expansion does not change
the expression or the splicing proﬁle of NOP36, but it induces the nucle-
ar accumulation of GGCCUG RNA foci in lymphoblastoid cell lines de-
rived from SCA36 patients [30]. SRSF2 binds to the SCA36 repeat in
vitro and partially co-localises with RNA foci in vivo [30]. In addition,
the expansion downregulates miR1292, a microRNA located immedi-
ately downstream to the repeat [30]. As a result, SCA36molecular path-
ogenesis might result from the combinatorial effect of toxic RNA
mechanismsmediated by sequestration and inactivation of SRSF2 splic-
ing regulator, and the dysregulation of miR1292 targets. So far no ani-
mal model has been generated to explore the contribution of these
two pathways to disease development.5.8. Amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
characterised by a selective degeneration of motor neurons. Several
families present a combination of frontotemporal dementia (FTD) with
ALS symptoms [172]. Recently, the abnormal expansion of a GGGGCC
hexanucleotide repeat has been identiﬁed as the most frequent genetic
cause of both conditions [32,173]. Two possible mechanisms might be
involved. One of them suggests that C9ORF72 transcripts containing
intronic GGGGCC repeat expansions accumulate in the nucleus of
human brain cells and spinal cord [32], predicting a disease mechanism
mediated by RNA toxicity. The GGGGCC motif predicts the potential
binding of hnRNP A2/B1 and SRSF1 [32], establishing possible similari-
ties with FXTAS and SCA31, respectively. An alternative mechanism of
loss of function is grounded on the 50% reduction of at least one of the
C9ORF72 transcripts in expanded repeat carriers [32,173]. The develop-
ment of cell and animal models, either through inactivation of C9ORF72
or overexpression of expanded transcripts, may help to resolve disease
pathobiology, and aid in identifying RNA-interacting proteins involved
in repeat-associated ALS/FTD pathogenesis.
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A subset of DM-associated splicing events also occurs in a trans-
genic mouse model of SBMA, which carries a coding CAG repeat ex-
pansion in the mouse androgen receptor (Ar) gene. These splicing
abnormalities are associated with CELF1 upregulation [174]. How-
ever, in contrast with DM, expanded RNA transcripts do not accumu-
late in nuclear foci, neither has an antisense RNA been detected in
transgenic mice, discarding a deleterious effect of CUG RNA repeats.
The expression of expanded CAG-containing transcripts is not sufﬁ-
cient to induce missplicing in SBMA. Instead, splicing dysregulation
appears to be directly mediated by the expanded polyglutamine pro-
tein [174], possibly through its abnormal and uncharacterised inter-
actions with CELF1.
Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autoso-
mal dominant disease characterised byprogressive ptosis, dysphagia and
limb muscle weakness. OPMD is caused by the abnormal expansion of a
polyalanine tract in N-terminal of the poly(A)-binding protein, nuclear 1
(PABPN1) [175]. Although missplicing has not been described in OPMD,
CELF1 is upregulated in cell models [176], raising the possibility of path-
ogenic events shared with DM1. However, in contrast with DM1, CELF1
co-localises with the characteristic intranuclear inclusions that accumu-
late in muscle of OPMD patients [176]. CELF1 upregulation might result
from a compensatory mechanism to counteract the sequestration of
this splicing factor. The opposing effects of CELF1 sequestration and
upregulationmake it difﬁcult to estimate the outcome on CELF1 activity.
Transgenic mice expressing an expanded human PABPN1 gene [177]
could help in addressing this question and the study of CELF1 targets in
OPMD.
Animal models have provided evidence to support some unifying
aspects shared by toxic RNA disorders (Fig. 3). Despite some recur-
rent themes, such as RNA accumulation and abnormal protein in-
teractions, disease-speciﬁc variations make each human condition
unique, and make it difﬁcult to conceive a universal pathway of mo-
lecular pathogenesis.
6. Unﬁtting pieces of the puzzle: Unresolved questions
The work in DM1 had driven us towards a prevalent model of
RNA-mediated pathogenesis centred on the abnormal accumulation
of toxic transcripts in the cell, and the establishment of deleterious
RNA–protein interactions. As a result, disturbed RNA-binding pro-
teins disrupt proper cell functions leading to the onset of disease
symptoms. However, some experimental observations do not ﬁt this
model, raising relevant questions that will contribute to a better un-
derstanding of disease mechanisms.
Despite the central role of RNA foci and MBNL1 sequestration
(Fig. 3), animal models have demonstrated that these disease features
are neither sufﬁcient nor required to elicit a phenotype (Table 1).
Transgenic ﬂies expressing untranslated CUG repeats and accumulat-
ing muscleblind-containing nuclear RNA foci developed no pheno-
type, showing that ribonuclear aggregates are not always causative
of disease [67]. Conversely, DM-associated phenotypes have been rec-
reated in transgenic mice that overexpress short CTG repeats in the
absence of morphological foci andMBNL sequestration [178]. The sur-
prising phenotype of mice expressing short triplet repeats likely
reﬂects the high expression levels of the transgene. Indeed, the compar-
ison of CUG-containing transcripts between different transgenic models
by northern blot analysis revealed higher expression in the skeletalmus-
cle of conditional mice expressing short DMPK transcripts than in any
other mouse model tested [178]. The overexpression of wild-type
DMPK-3′UTR carrying short CTG repeatsmay therefore be pathogenically
equivalent to the expression of fewer transcripts carrying large CTG
expansions.
Given the dissociation between foci formation and the disruption of
alternative splicing in transfected cell cultures [129] and in a DM1mouse model [178], the contribution of Cnbp haploinsufﬁciency to the
DM2 phenotype has been investigated. Heterozygous Cnbp+/−mice de-
veloped relevant DM phenotypes, such as myotonia, ocular cataracts,
cardiac arrhythmia, defective walking, both proximal and distal muscle
wasting as well as histological abnormalities in skeletal muscle and
heart [179]. The development and characterisation of this transgenic
line has raised questions about the unresolved effect of the CCTG
tetranucleotide repeat expansion on CNBP expression levels in DM2 pa-
tients. While total CNBP protein and transcript in human DM2 muscle
samples and cell cultures appeared originally unchanged [180,181],
others have then reported reduced levels in DM2 myoblasts [182] and
muscle biopsies [183]. Although toxic RNA effects likely explain the
overlapping phenotypes between DM1 and DM2, abnormal CNBP levels
in DM2 may account for disease-speciﬁc manifestations. The unexpect-
ed role of CNBP haploinsufﬁency in DM2pathogenesismayprompt us to
revisit an old question: what if the decreased expression of DMPK and
SIX5 reported in DM1 contributed to disease phenotypes [184–187]?
Knock-out mice showed that Dmpk and Six5 inactivation per se were
not the primary cause of disease [188–191]. However, the late muscle
and cardiac abnormalities in these lines do not exclude an increased sus-
ceptibility to disease in the presence of toxic repeats. This hypothesis
could be addressed through the inactivation of Dmpk and Six5 in
CUG-expressing mice. If a contributing role is found for Dmpk or Six5,
therapies targeting toxic RNA must be reassessed and possibly com-
plemented with strategies to compensate DMPK and SIX5 decreased
levels.
Finally, attractive as it is, the unpredicted RAN translation of expand-
ed transcripts brings up another unresolved question: how can expand-
ed RNA repeats trapped in the cell nucleus be translated into protein?
The labile nature of nuclear RNA aggregates, as constantly forming
and disaggregating structures [192], may provide an answer. Expanded
RNA transcripts might be temporarily free in the cell and not always
stuck in the nucleus, allowing not only RAN translation to occur, but
also the establishment of abnormal interactions with proteins that
may selectively bind to soluble RNA. Interestingly, a screening for
MBNL1-interacting partners affected by the CTG repeat expansion iden-
tiﬁed multiple proteins that contribute to DM1 spliceopathy without
co-localising with RNA-foci [193], like CELF1. These observations are
consistent with a role for soluble expanded RNA transcripts in patho-
genic events outside ribonuclear aggregates, where they may partici-
pate in disease-associated molecular events.
7. Hitting where it hurts: Therapeutic targeting of toxic RNA
Symptomatic medication is available for some RNA-mediated dis-
orders, but in general it is only moderately effective, because it inter-
feres with events far downstream of the primary cause of disease.
However, insight into the pathobiological cascade has identiﬁed mo-
lecular events that could potentially be targeted by novel therapeutic
strategies— this is particularly true in the case of DM. The rational de-
sign of molecular therapies in vitro or in vivo has been reviewed else-
where [66,194,195]. In the following section we will concentrate on
the contribution of animal models of toxic RNA to the development
of approaches to neutralize the deleterious effects of expanded tran-
scripts, focusing mainly on DM as the paradigm of toxic RNA disor-
ders (Table 2).
7.1. Reversible nature of the DM phenotype
The use of animal models provided evidence that CUG-induced
toxicity can be suppressed, opening avenues to the development of
novel molecular therapies. Conditional transgenic mice overexpressing
high levels of short DMPK transcripts display many of the phenotypes
observed in DM1 patients, including cardiac conduction deﬁcits, myo-
tonic discharges, muscle weakness, splicing abnormalities, histopatho-
logic changes and CELF1 upregulation (but no RNA foci or MBNL
Table 2
Examples of therapeutic strategies developed to target RNA toxicity in animal models of disease.
Therapeutic strategies Strategy; type of administration Mouse model Effect on RNA foci Effect on splicing Effect on phenotype References
Shutting down gene expression (proof of
principle experiment)
Inducible transgene construct (CTG)5
overexpression
Not applicable Reversion of
missplicing
Correction of myotonia and
cardiac conduction defects
[178]
MBNL1 expression restoration MBNL1 overexpression; AAV-mediated
muscular infection
HSALR Diffuse MBNL1 distribution Reversion of
missplicing
Correction of myotonia [196]
MBNL1 overexpression; breeding with
overexpressing mouse line
HSALR Foci present in MBNL1-overexpressing mice Missplicing prevented Correction of myotonia and
myopathy
[197]
CELF1 normal phosphorylation restoration Use of PKC inhibitors; i.p. injection EpA960 No change Reversion of
CELF1-dependent
missplicing
Improved survival and cardiac
function.
[199]
CELF1 inactivation Expression of CELF1 dominant negative;
breeding with CELF1Δ mouse line
HSALR Not reported Reversion of
CELF1-dependent
missplicing
Not reported [200]
Elimination of the toxic transcripts (unknown
mechanism or RNase H-mediated)
ASO; intramuscular injection HSALR 40% reduction in MBNL1-positive foci; 50% re-
duction in expanded CUG transcripts
Reversion of
missplicing
No correction of myotonia [34]
ASO; intramuscular injection EpA960 (muscle
expression)
40% reduction in number of foci per cell; 50%
reduction in expanded CUG transcripts
Slight reversion of
missplicing
Gapmers induce histological
changes in muscle
[37]
siRNA; intramuscular injection HSALR Smaller and fewer foci; 70–80% reduction of
expanded CUG RNA
Reversion of
missplicing
Correction of myotonia [204]
ASO; systemic administration HSALR Smaller and fewer foci detected; 80% reduction
in expanded CUG transcripts
Reversion of
missplicing
Sustained correction of
myotonia
[36]
U7-snRNP; lentiviral mediated
transduction
Only in cultured
DM1 muscle cells
~60% reduction in foci number; 70–80%
reduction in expanded DMPK transcripts
Reversion of
missplicing
Strategy only tested in cellulo [203]
Block the access to RNA binding proteins ASO; intramuscular injection HSALR Reduction in foci number; 50% reduction in
expanded CUG transcripts
Reversion of
missplicing
Correction of myotonia [35]
ASO; i.v. injection HSALR Reduction in foci number; 50% reduction in
expanded CUG transcripts
Reversion of
missplicing
Correction of myotonia [205]
Pentamidine; i.p. injection HSALR Reduction in number of foci (in cultured cells) Partial reversion of
missplicing
Not reported [207]
Hoechst 33258 variants; i.p. injection HSALR Reduction in number of foci (in cell culture
model of DM1)
Partial reversion of
missplicing
Not reported [210]
D amino acid hexapeptide; oral
administration
(CUG)480
expressing
Drosophila
70% reduction in foci number Not reported Suppression of lethality and
muscle degeneration
[38]
D amino acid hexapeptide; intramuscular
injection
HSALR Reduction in foci number Partial reversion of
missplicing
Correction of histopathology
Reduction of trinucleotide repeat expansion ASO; intramuscular injection DM300 Reduction in number of foci (in cultured cells) Not reported Stabilisation of expanded CTG
DNA repeats
[206]
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toxic RNA in this inducible line led to suppression of the phenotype
[178]. This result provided proof of principle that DM-associated symp-
toms are reversible through direct targeting of the primary pathogenic
molecule: the toxic RNA (Table 2).
Phenotype reversal can also be attained by the modulation of the
levels and/or activity of splicing factors affected by disease pathogenesis.
The overexpression of MBNL1 in transgenic ﬂies [68] and mice [196]
expressing toxic CUG transcripts corrected their DM-associated pheno-
types. MBNL1 overexpression in the skeletal muscle of HSALR transgenic
mice was initially achieved through local injection of recombinant
adeno-associated viral vectors, and resulted in correction of adult splic-
ing and suppression of myotonia [196]. Later, the generation of an
overexpressing line demonstrated that systemic and sustained MBNL1
overexpression is well tolerated, and it conﬁrmed the therapeutic bene-
ﬁts of MBNL1 replacement in the skeletal muscle of DM1mousemodels
[197]. The beneﬁts of elevated MBNL1 overexpression in other tissues
and organ systems remain to be assessed. Since MBNL1 sequestration
by RNA foci has also been implicated in SCA8, HDL2 and FXTAS, this
strategy might be of value in other human diseases. The situation is
less clear in CAG expansion disorders. Despite MBNL1 sequestration by
CAG-containing foci, contradictory results have been reported upon
overexpression in animal models of CAG toxicity: while rescuing the
phenotype of transgenic C. elegans [198], it enhances neurodegeneration
in CAG transgenic ﬂies [74].
Pharmacological modulation of CELF1 steady-state levels in the
heart of transgenic mice expressing expanded CUG transcripts has
pointed to CELF1 as another putative therapeutic target. The signalling
pathway triggered by the expression of expanded CUG transcripts and
leading to PKC-mediated CELF1 hyperphosphorylation remains un-
known. Nevertheless, the administration of PKC inhibitors to induced
EpA960 mice decreased CELF1 hyperphosphorylation, reduced protein
steady-state levels in heart, corrected CELF1-dependent alternative
splicing, and improved the cardiac conduction and contractile abnor-
malities [199]. Similarly, the expression of a CELF1 dominant negative
protein in skeletal muscle rescued splicing dysregulation of CELF1-
dependent targets in HSALR mice, expressing toxic repeats [200].
The implications of CELF1 in other toxic RNA diseases are unclear.
In contrast to DM1, CELF2 upregulation has not been reported in DM2
[51] and it may even have a protective role in other conditions, such
as FXTAS [146]. Furthermore, while CELF1 is an important disease in-
termediate in heart and skeletal muscle, other members of the CELF
family may play predominant roles in other tissues, such as CELF2
in the CNS [60]. In conclusion, the use of CELF downregulation thera-
pies requires further investigation in DM.
Increased levels of STAU1 (staufen, RNA binding protein, homolog 1)
have also been found in the skeletal muscle of DM1 patients and HSALR
mice [201]. But in clear contrast to the role of CELF1 in DM1, STAU1
upregulation is likely protective, since it enhances nuclear export and
translation of CUG-containing transcripts trapped in the nucleus [201].
STAU1 overexpressionmay therefore provide an alternative therapeutic
strategy, which can now be tested in other DM1 animal models.
Rather than establishing the grounds of future therapies, these re-
sults provided important proof of principle of the reversibility of dis-
ease, and opened new avenues to the development of promising
therapeutic strategies. These can be broadly grouped into strategies
to degrade the expanded RNA or to inhibit its toxic effects in the cell.
7.2. Degradation of pathogenic RNA
The development of antisense technology allows direct targeting
of toxic RNA transcripts. To be effective as therapeutics, antisense
oligonucleotides (ASO) must reach and selectively hybridise to the
target RNA. This requires sufﬁcient half-life within tissues, appropri-
ate biodistribution and efﬁcient uptake. Chemical modiﬁcations can
be introduced into ASO molecules to optimise these parameters,increase their efﬁciency and minimise off-target effects [202]. As a re-
sult, modiﬁed ASO have been successfully used in transgenic mouse
models of DM1 to eliminate toxic CUG transcripts.
2′-O-methyl phosphorothioate-modiﬁed (2OMe) ASO have been
developed to directly target the expanded CUG RNA expansion, using
a (CAG)7 sequence design. Local administration of 2OMe oligonucleo-
tides into the skeletal muscle of DM1 mouse models expressing non-
coding CTG expansions, reduced the levels of the toxic transcripts by
~30–70% [34]. As a result, the number of RNA foci decreased signiﬁcant-
ly, MBNL1 displayed a more diffuse distribution and typical DM1 splic-
ing abnormalities improved, albeit to a degree that was not sufﬁcient to
reduce myotonia [34] (Table 2).
It is important to note that DM1 patients carry a functional copy of
the DMPK gene. Although full Dmpk depletion in mice produces only a
mild phenotype at later ages [188,189], ASO-based therapies must spe-
ciﬁcally mark the expanded RNA for degradation, leaving the non-
expanded as well as other short CUG-containing transcripts intact. The
short CAG repeat sequences in the 2OMeASO used in this study allowed
speciﬁcity for the mutant RNA, over transcripts containing short CUG
repeats [34], limiting off-target effects. Similarly, CAG-containing U7-
snRNA antisense sequences speciﬁcally targeted the expanded DMPK
mRNA in culturedDM1muscle cells (Table 2), while preserving the levels
of the short DMPK RNA molecules [203]. The beneﬁts of lentiviral-
mediated delivery of U7-snRNA in DM1 transgenic mice must be
evaluated.
Alternatively, speciﬁcity towards the pathogenic transcript might
be grounded on the nuclear location of expanded DMPK transcripts
and activation of RNase H-mediated pathways of RNA degradation.
Since RNase H is enriched in the nucleus, it might be particularly efﬁ-
cient to degrade transcripts that accumulate in the nucleus of DM1
cells. To test this hypothesis, gapmer ASO containing CAG sequences
have been designed to activate RNase H-mediated degradation.
Local injection of gapmer ASO into the skeletal muscle of EpA960
mice was sufﬁcient to decrease the levels of expanded transcript by
50%, reduce the number of foci per nucleus and to induce partial cor-
rection of DM1-associated spliceopathy [37] (Table 2).
In addition to ASO strategies, siRNA duplexes have also been used
to induce selective cleavage of expanded CUG transcripts. The intra-
muscular injection of a siCAG in HSALR mice resulted in a 70–80% re-
duction in toxic transcripts, decreased number of foci and correction
of missplicing and myotonia [204] (Table 2).
Despite these encouraging results, the development of efﬁcient
therapies for DM was still facing an important challenge: DM is not
only a muscle disease, but if affects many other tissues, such as the
CNS and heart. Administration, biodistribution and stability of the
therapeutic agent must be optimised to reach all the affected tissues.
Although expressing CUG toxic transcripts speciﬁcally in the skeletal
muscle, the HSALR mice have offered means to test systemic routes
of administration. The subcutaneous injection of modiﬁed ASO (com-
patible with RNase H activity) into HSALR mice resulted in a robust
and sustained decrease of toxic RNA levels by 80%, decrease in RNA
foci, improvement of alternative splicing, elimination of myotonic
discharges and normalisation of the transcriptome (Table 2). The ef-
fect was detected two weeks following ASO administration and
persisted over one year, demonstrating the selective susceptibility
of nuclear trapped transcripts to RNase H-dependent degradation,
as well as the long-term stability and bioactivity of the ASO molecules
[36]. Similarly, systemic delivery of CAG-containing morpholinos (see
Section 7.3) by intravenous injection redistributed MBNL1 protein,
corrected alternative splicing and eliminated myotonia in HSALR
mice [205]. Together, these results show that the physiological bene-
ﬁts of the therapeutic molecules do not require direct administration
into the affected tissue (the skeletal muscle in HSALR mice). Instead
ASO are properly distributed and efﬁciently diffused from the injec-
tion site, to reach distant tissues, while keeping their biological
activity. Nonetheless, the encouraging biodistribution of these
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in multisystemic mouse models, expressing the toxic CUG RNA in nu-
merous tissues and organs. A similar approach might be effective in
other genetic disorders characterised by the nuclear accumulation
of toxic RNA, such as FXTAS, SCA8 and ALS/FTD.
7.3. Inhibition of abnormal and pathogenic RNA–protein interactions
A second approach to reduce RNA dominance involves the preven-
tion of abnormal interactions between toxic transcripts and RNA-
binding proteins, either through the use ASO working by steric hin-
drance or small molecules
(CAG)25morpholino ASOwere designed to bindCUGRNA repeat ex-
pansions with high afﬁnity. Local injection of (CAG)25 morpholino ASO
into the skeletal muscle of HSALR transgenic mice inhibited the binding
of MBNL1 to the expanded RNA and redistributed the MBNL1 protein.
The partial correction of spliceopathy was sufﬁcient to eliminate myo-
tonia. The treatment has also resulted in an unexpected 50% reduction
in the levels of the expanded RNA, but left the endogenous transcripts
containing short CUG repeats unaltered [35]. Interestingly, this oligonu-
cleotide treatment not only halts RNA toxicity events, but it also sup-
presses somatic repeat expansion [206]. This result suggests that ASO
can modify trinucleotide repeat dynamics in vivo, providing means to
stabilise the repeat at subpathogenic repeat lengths and delaying dis-
ease onset (Table 2).
The high cost and pharmacological challenges of ASO-based therapies
steered some laboratories to search for alternative approaches. The use of
small molecules, for which delivery methods and biodistribution is less
problematic, would present an advantage over ASO protocols. A chemical
screening identiﬁed pentamidine as a small compoundwith a high afﬁn-
ity for CUG repeats, capable of inhibiting MBNL1 binding and sequestra-
tion by toxic RNA (Table 2). Although reverting the spliceopathy in the
skeletal muscle of HSALR mice [207], the therapeutic use of pentamidine
is limited by its high toxicity. The rational design of bioactive molecules
that target both DM1 and DM2 expanded RNAwith high afﬁnity resulted
in the identiﬁcation of non-toxic molecules that inhibit the CUG–MBNL1
interaction, such as benzo[g]quinoline derivatives [208], and Hoechst
33258 variant molecules [209]. Unfortunately, the improvement of
MBNL1-dependent splicing events in HSALR mice following administra-
tion of some of these compounds was modest [208]. Improved pentami-
dine and Hoescht 33258 ligands were identiﬁed by computational
searches for chemical similarity. One of these ligands partially reversed
DM1-associated missplicing when injected intraperitoneally in HSALR
mice [210]. Other bioactive smallmolecules have been reported to specif-
ically interactwithCUG, CAGandCGGexpandedRNA repeats and reverse
missplicing in cell culture [211–213]. Their efﬁcacy in animal models re-
mains to be tested.
Transgenic ﬂies expressing an interrupted CUG expansion also
helped in the identiﬁcation of a small hexapeptide that redistributes
muscleblind, reduces the number of RNA foci and suppresses the
CUG-induced phenotype in the brain, muscle and eye of transgenic
Drosophila (Table 2). In HSALR mice, local administration of the pep-
tide in skeletal muscle restored MBNL1 function, reversed missplicing
and centronucleopathy for at least four weeks after injection [38]. The
beneﬁts of systemic administration in skeletal muscle and other tis-
sues must be addressed in DM1 mouse models expressing toxic tran-
scripts in multiple tissues.
Advances in the understanding of the molecular bases of DM,
coupled with the progress made in the development of means to tar-
get RNA molecules in vivo, have led to the prospect of novel therapies
for DM (Table 2). The pre-clinical success of therapeutic strategies in
DM1 mouse models is remarkable, and moves us closer to the
long-awaited clinical trials in humans. Nevertheless, these molecules
are still facing some signiﬁcant hurdles, including CNS accessibility
and tolerability, as well as expensive manufacturing costs. Continued
research of chemistries that enhance the cellular uptake, potency andselectivity of action will substantially increase the clinical impact of
RNA-based therapies in the treatment of DM and other toxic RNA
diseases.
8. Conclusion
The diversity of DM1 animal models strongly contributed to clari-
fying the disease mechanisms mediated by toxic RNA molecules. The
DM paradigm of RNA toxicity contributed to understand the molecu-
lar pathogenesis of other repeat expansion disorders, which share the
typical accumulation of toxic transcripts in ribonuclear foci. The
downstream pathogenesis is usually mediated by abnormal interac-
tion of toxic RNA molecules with RNA-binding proteins, resulting in
dysregulation of RNA metabolism, and in particular alternative splic-
ing. Animal models were developed by independent laboratories and
paved the way to the dissection of disease-causing mechanisms me-
diated by missplicing events. Today, these lines continue to reﬁne
our understanding of disease pathogenesis, providing substantial ev-
idence that DM mechanisms are not limited to spliceopathy. In fact,
abnormal gene expression, protein translation, RNA localisation and
miRNA metabolism are likely involved, not only in DM but also in
other toxic RNA diseases. The clear characterisation of the pathogenic
events from disease mutation to clinical manifestations, and their
phenotypic implications in DM has been paramount to develop ratio-
nal and efﬁcient molecular therapies. The vast collection of animal
models of RNA toxicity currently available has accelerated research
progress towards a solid understanding of disease biology, and pro-
vided valuable tools for the pre-clinical assessment of future
therapies.
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